Peter Neupert Sells 124,690 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Director Peter Neupert sold 124,690 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $25.15, for a total transaction of $3,135,953.50. Following the completion of the transaction, the director owned 130,625 shares of the company’s stock, valued at approximately $3,285,218.75. This trade represents a 48.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT opened at $25.44 on Friday. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $26.16. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The stock has a market capitalization of $4.06 billion, a PE ratio of -62.05 and a beta of 2.08. The stock’s 50-day moving average price is $21.89 and its 200-day moving average price is $17.28.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The business had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.17) EPS. As a group, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

Institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $28,000. Allworth Financial LP acquired a new position in Adaptive Biotechnologies in the 2nd quarter valued at $35,000. EverSource Wealth Advisors LLC lifted its holdings in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. KBC Group NV acquired a new stake in Adaptive Biotechnologies during the 1st quarter worth $45,000. Finally, Assetmark Inc. boosted its stake in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. BTIG Research increased their target price on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Piper Sandler upped their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Morgan Stanley increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. TD Cowen lifted their target price on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, JPMorgan Chase & Co. cut their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.42.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Analysts maintain a broadly constructive view, with five Buy ratings, one Hold and one Sell. BTIG Research and TD Cowen recently raised their price targets to $25 and $28, respectively, while the consensus rating remains “Moderate Buy.” Analyst and stock information
• Positive Sentiment: Institutional ownership remains high at 99.17%, and several hedge funds increased their positions, including Jennison Associates, which more than doubled its stake. Institutional ownership information
• Positive Sentiment: The company’s latest quarterly revenue reached $71.55 million, exceeding estimates of $65.44 million and increasing 21.5% year over year, supporting the growth case for its immune-receptor sequencing business. Quarterly results
• Neutral Sentiment: ADPT has rallied substantially, trading near its 52-week high and above both its 50-day and 200-day moving averages. However, the consensus price target of $24.42 is below recently reported trading levels, suggesting limited near-term upside based on current estimates.
• Negative Sentiment: Multiple insiders sold substantial positions: CEO Chad Robins sold approximately 600,000 shares for nearly $14.9 million across August 17–18, while Director Peter Neupert sold 124,690 shares for $3.14 million and Director Robert Hershberg sold 30,664 shares for $748,000. The transactions reduced the directors’ holdings by roughly 40%–49% and the CEO’s ownership by about 11%–13%, potentially weighing on investor confidence. Insider selling report
• Negative Sentiment: Adaptive Biotechnologies missed quarterly EPS expectations, reporting a loss of $0.25 per share versus the anticipated loss of $0.13. The company remains unprofitable, with analysts expecting a full-year loss of approximately $0.40 per share.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.